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Elevated glutamate is implicated in the pathology of PDR. The ability to rapidly assess the glutamate and amino acid content
of vitreous provides a more complete picture of the chemical changes occurring at the diabetic retina and may lead to a better
understanding of the pathology of PDR. Vitreous humor was collected following vitrectomies of patients with PDR and control
conditions of macular hole or epiretinal membrane. A capillary electrophoresis method was developed to quantify glutamate and
arginine. The analysis is relatively fast (<6 minutes) and utilizes a poly(ethylene)oxide and sodium dodecylsulfate run buﬀer. Both
amino acid levels show signiﬁcant increases in PDR patients versus controls and are comparable to other reports. The levels of
vitreal glutamate vary inversely with the degree of observed hemorrhage. The results demonstrate a rapid method for assessment
of a number of amino acids to characterize the chemical changes at the diabetic retina to better understand tissue changes and
potentially identify new treatments.
Copyright © 2007 Miao-Jen Lu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Signaling amino acids, including glutamate, γ-aminobutyric
acid (GABA), and arginine are present in the vitreous and
appear to play key roles in the pathology of variety eye disor-
ders. Glutamate is one of the excitatory neurotransmitters in
the retina. When it is present at high levels, it can over stim-
ulate the N-methyl-D-aspartate type glutamate receptors on
the ganglion cells of the retina and cause damage to the gan-
glion cells [1, 2]. GABA is an important inhibitory neuro-
transmitter in the retina and arginine, an essential amino
acid, is also the precursor of the signaling molecule, nitric
oxide (NO) [3]. The retinal vasculature is auto regulated and
this appears to be related to nitric oxide [4]. In addition,
there appears to be a relationship between nitric oxide and
glutamate [5]. There are a few studies which have shown that
in proliferative diabetic retinopathy (PDR), the levels of glu-
tamate may be elevated [6]. Considering the fact that there
are now glutamate antagonists that help in other diseases, it
is important to do further studies to determine if the eleva-
tionsofsignalingaminoacidslikeglutamateandarginineare
elevated and therefore developing a rapid and better resolu-
tion method is necessary for vitreous analysis
The vitreous is a chemically complex solution of carbo-
hydrates, proteins, and small molecules. A number of an-
alytical methods had been developed for vitreous analy-
sis. Proteomic analysis via 2D gel electrophoresis with liq-
uidchromatographyelectrospraytandemmassspectrometry
(LC MS/MS) is the common strategy for proteins analysis in
vitreous with or without diabetic retinopathy [7]. The use
of enzyme-linked immunsorbet assays for preselected pro-
tein growth factors has been another approach [8, 9]. Small
molecule analytes such as ascorbic acid [10], glutamate and
GABA [11] have been evaluated with high-pressure liquid
chromatography (HPLC) and HPLC coupled with electro-
chemical detection. Capillary electrophoresis-laser induced
ﬂuorescence (CE-LIF) is a powerful analytical tool for mi-
croliter to nanoliter volume biosample analysis that aﬀords
a number of advantages including faster separations, lower
sample volume consumption, high resolution separations,
and low limits of detection [12]. This technique has been
used to evaluate inorganic ions in clinical vitreous samples
[13–15]. We have previously described the use of CE for
amino acid analysis of push-pull perfusates of the rat vitre-
ous [16]. To date, there have been no reports of CE analysis
of vitreous for amino acids separations that take advantage
of the separation speed and resolution for understanding the
chemical changes with diabetic retinopathy. In this study, we
show further evidence that there is an elevation in glutamate
and other signaling amino acids in PDR by using a rapid CE.2 Experimental Diabetes Research
Table 1: Patient characteristics.
Control (ERM/MH) PDR
Sex (M/F) 11/14 9/9
Type1/Type 2/no diabetes 0/4/21 4/14
Age (mean ± SEM, years) 67 ±25 3 ±3
Duration of diabetes (mean ± SEM, years) 10 ±31 9 ±2
Blood glucose (mean ± SEM, mg/dl) 113 ±10a 151 ±21b
Vitreous hemorrhage (−, +1, +2, +3)c 25, 0, 0, 0 1, 4, 7, 6
Traction detachment (−, +1, +2, +3)d 25, 0, 0, 0 14, 3, 0, 1
an = 21, bn = 16, c ‘−’ = none, +1 = mild, +2 = moderate, +3 = severe, d ‘−’ = none, +1 = mild-focal area, +2 = moderate-area less than 2dd, +3 = severe
Two separation conditions were explored in this study. The
stability of amino acids from vitreous samples was also stud-
ied to improve monitoring of amino acid quantiﬁcation.
2. EXPERIMENTAL
2.1. Chemicals
All chemicals were analytical grade and were purchased from
Sigma(Sigma-Aldrich,St.Louis,MO,USA)unlessotherwise
noted. The labeling reagent 3-4-carboxybenzoyl quinoline-
2-carboxaldehyde (CBQCA) was purchased from Molecu-
lar probes (Eugene, OR, USA). Sodium tetraborate, sodium
phosphate, sodium dodecyl sulfate (SDS), β-cyclodextrin (β-
CD), sodium hydroxide, sodium chloride (NaCl), potas-
sium cyanide (KCN) were purchased from Acors (Fisher,
Somerville, NJ, USA). Run buﬀe ra n da c e t i ca c i ds o l u t i o n
were freshly prepared in ultraﬁltered, deionized water pro-
duced by US Filter puriﬁcation system (Lowell, MA, USA).
2.2. Vitreoussamples
This study was performed with institutional review board
approvals at the participating institutions; the University
of Illinois Chicago, Chicago, IL, Saint Francis Hospital,
Charleston, WV, and the Mayo Clinic, Rochester, MN. The
characteristics of the patient population is summarized
in Table 1. Patients undergoing vitrectomy for idiopathic
epiretinal membranes or idiopathic macular holes and who
had no other ocular problems served as controls (n = 25) to
compare to those who had vitrectomy for PDR with hemor-
rhage classiﬁed from none to severe (n = 18). At the start of
the vitrectomy, before the infusion was started, a pure vitre-
ous sample was removed with the vitrector and 100μLv o l -
ume of vitreous was pipetted into centrifuge tube that con-
tained 100μL1Ma c e t i ca c i d( p H2∼ 3) to deactivate en-
dogenous proteases. Vitreous samples of patients were deliv-
ered to University of Illinois at Chicago by overnight courier.
Analysis of 2μL aliquots began with derivatization of vit-
reous amino acids with 2μl 20mM CBQCA in the presence
of2μl10mMcyanide.BecausethepHvalueofvitreoussam-
ples (pH 2-3) was not compatible with the derivatization re-
action, the cyanide solution was prepared in 250mM phos-
phate buﬀer with pH 10 to adjust the pH. The reaction mix-
ture of vitreous sample and CBQCA was allowed to react for
2hoursatroomtemperaturepriortoCE-LIFanalysissimilar
to previously published results [16].
2.3. RunningconditionforMEKCmethod
Aseparationmethodforlow-ﬂowpush-pullperfusatesofthe
rat vitreous had been described previously [16]. These con-
ditions were tried in this study. The run buﬀer consisted of
20 mM sodium tetraborate (pH 9.3), 20mM sodium chlo-
ride, 45mM sodium dodecyl sulfate (SDS), and 55mM β-
cyclodextrin (β-CD). In order to explore a faster separation
for these studies, the capillary was reduced to 40cm (30cm
eﬀectivelength).Allseparationswereperformedat17kVap-
plied voltage.
2.4. RunningconditionsforMEKC-PEOmethod
An alternative separation method was developed using 0.6%
linear polymer, polyethylene oxide (PEO; MW = 600kDa)
added to the separation buﬀer. PEO was prepared in 20mM
sodium tetraborate (pH 9.3), 20mM sodium chloride, and
75mM sodium dodecyl sulfate (SDS) run buﬀer. Before in-
troducing sample into capillary, the capillary has been rinsed
with 50mM sodium tetraborate buﬀer (pH 9.3) to ﬁll the
capillary with a low viscosity solution to allow gravimetric
injection. The separation was performed with the inlet end
of the capillary in the PEO buﬀer at 16kV applied voltage.
2.5. InstrumentationofCE-LIF
The CE-LIF system used in these studies has been described
previously [16]. Brieﬂy, the system was built in-house with
a high voltage power supply (Spellman, Hauppage, NY,
USA), a Zetalif Lif detector (Picometrics, Paris, France), and
an argon ion laser (Coherent, Santa Clara, CA, USA) at
488nm. Buﬀer vials were placed in a plexiglass box to iso-
late high voltages. The LabView programming environment
(National Instruments, Austin, TX) was used with a cus-
tom program for instrument control and data acquisition.
All CE analyses were performed at room temperature with a
40cm × 360μmO . D .× 50μmI . D .( 3 0c me ﬀective length)
fused-silica capillaries (BioTAQ, Gaithersburg, MD, USA).
In this work, gravimetric sample injection was used with a
30cm height diﬀerence for 5 seconds.Miao-Jen Lu et al. 3
2.6. Dataanalysis
The collected data were analyzed with Microsoft Excel and
Class Eleganza CE station software V5.5 (Ayer Rajah Indus-
trial Estate, Singapore). Amino acid quantiﬁcation was per-
formed with calibration curves. In order to conﬁrm the va-
lidity of amino acids concentration determinations from cal-
ibration curves, the method of standard additions was used
randomly with a number of vitreous samples for compari-
son. An F-test was performed to evaluate the equivalence of
control and PDRdata set variances forthe appropriate appli-
cation of a nonpaired student’s t-test to determine statistical
signiﬁcance. A one-way ANOVA (P<. 05) was performed on
amino acid data for groups of low/moderate/high levels of
vitreal hemorrhage.
3. RESULTS AND DISCUSSIONS
3.1. Newseparationmethodforchemicallycomplex
humanvitreoussamples
The goal of this project was to explore the combination of
MEKC with a highly viscous buﬀer, in this case a PEO-
containing solution. The analysis of small molecule amino
acids is compared with a previous method in terms of its
speed and resolution. The optimized separation conditions
are then used for the clinical analysis of a number of vitreous
samples.
3.1.1. Useofdevelopedmethodforratvitreous
perfusate-MEKCmethod
In the beginning of this work, the separation condition that
h a db e e nd e s c r i b e dp r e v i o u s l y[ 16] was evaluated the use
for human vitreous samples. This separation condition is the
MEKC method. The developed separation method was used
for amino acids analysis for rat vitreous perfusates. In or-
der to do relatively faster separations, we decreased the capil-
lary length down to 40cm compared to previous work to de-
crease the analysis time by 50% (<5 minutes) (see Figure 1).
Because rat vitreous perfusates and human vitreous samples
arequitediﬀerentespeciallysincetherewasadditionofacetic
acidintohumanvitreoussamplestodeactivateproteases,the
separation based on the MEKC method applied to human
vitreous analysis did not separate the peaks as well as in the
rat vitreous perfusates.
3.1.2. NewlydevelopedMEKC-PEOmethodforaminoacid
analysisofhumanvitreous
DevelopmentofMEKC-PEOmethod
Polyethylene oxide (PEO) had been used for small molecules
analysisofbody ﬂuids,butitis usuallyusedasastacking ma-
trix in CE separation. Because the PEO would increase the
viscosity of the separation buﬀer, this aﬀects the eﬃciency of
hydrodynamic sample injection. The capillary was ﬁlled with
50mMboratebuﬀerastheleadingbuﬀertoallowsamplein-
jection as well as regenerate high and reproducible electroos-
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Figure 1: Electropherogram of MEKC method. MEKC method was
developed for rat vitreous perfusate. The following is the separation
conditionforMEKCmethod.Capillaryusedforseparationis40cm
in total length and 30cm in eﬀective length. Composition of the
run buﬀer is 20mM sodium tetraborate, 20mM sodium chloride,
45mM sodium dodecyl sulfate (SDS), and 55mM β-cyclodextrane
(β-CD). Sample injection is 5 seconds by hydrodynamic injection
and the separation was conducted at 17kV. Note the poor separa-
tion of the peaks following three minutes.
motic ﬂow. A solution of ﬁfteen amino acids was used to de-
termine if PEO as a sieving matrix could help in improving
the resolution of amino acids. Figure 2(a) shows that only 7
peaks were resolved out of 15 amino acids so using PEO as a
sieving mechanism was not suﬃcient to separate the amino
acids. Therefore we used PEO coupled with MEKC method
to improve the resolution. Sodium dodecyl sulfate (SDS) is
the most common surfactant used for micellar electrokinetic
chromatography (MEKC). SDS concentrations in the 25–
100mM range were evaluated for optimization. The 75mM
SDS addition gave the best separation and peak shapes. This
allowed successful separation of 14 peaks out of 15 amino
acids (see Figure 2(b)). Applying the optimized condition to
vitreous sample analysis showed that with SDS and PEO, a
better resolution wasachieved within 6 minutes compared to
prior methods used in previous studies from other research
groups (see Figure 3).
From the results, we hypothesize that in our MEKC-PEO
method, the micelles interact with PEO to improve the res-
olution by increasing the diﬀerence of mobility of neutral
small molecules, such as amino acids. In addition, the PEO
molecules would absorb to the capillary wall thereby pre-
venting proteins from adhering. This would allow better sep-
aration of complex biosamples which contain a variety of
proteins.
The MEKC-PEO method does not provide the ability to
separate D-a n dL- serine as the MEKC method also em-
ploys the chiral selector, β-cyclodextrin. Common to both
methods is the fact that GABA is either not found [16]
with the MEKC buﬀer or coelutes with Ser with the MEKC-
PEO buﬀer. Improved detector sensitivity will be needed to
quantify GABA. However, the amino acid taurine is easily4 Experimental Diabetes Research
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Figure 2: Separation of amino acid standards in MEKC-PEO
method,(a)0mMSDSand(b)75mMSDS.Separationbuﬀercom-
posed by 0.6% polyethylene oxide (PEO), 20mM sodium tetrabo-
rate, and 20mM sodium chloride. Before introducing sample into
capillary, capillary was ﬁlled out with 50mM sodium tetraborate
buﬀer and following by sample injection through hydrodynamic
injection. After sample injection, separation buﬀer was introduced
into capillary by electro-osmotic ﬂow (EOF) and separation was
conducted at 16kV. Electropherogram of standard amino acid mix-
ture. Identiﬁcation is shown in (b) as follows: 1: Arginine, 2: His-
tamine, 3: Lysine, 4: Methionine, 5: Histidine, 6: Phenylalanine, 7:
Valine, 8: Serine, GABA, 9: Tyrosine, 10: Alanine, 11: Taurine, 12:
Glycine, 13: Glutamate, 14: Aspartate.
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Figure 3: Representative electropherogram of a vitreous sample.
Separation condition is the same as Figure 2(b).
separated by the MEKC-PEO method in contrast to the
MEKC method.
When PEO is used as a stacking matrix, a relatively long
(∼30 minutes) separation time is required due to the con-
centration of the amino acids from large plugs of sample so-
lution. In this case PEO is playing a role as a sieving matrix,
and allowed the analysis time to be shortened to less than 6
minutes.
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Figure 4: Electropherograms comparing human vitreous stability
over time. The separation conditions are the same as Figure 2 (b).
Electropherograms (a) compares the traces found at day 2 follow-
ing collection to one performed at one month following collection
and shows a large dissimilarity in peaks; (b) electropherograms per-
formed at 3 days and 10 days since vitreous sample collection shows
similar peaks. Electropherograms (a) and (b) are from diﬀerent pa-
tients. The stability of human vitreous sample begins to degrade
after two weeks since the time of collection.
3.2. Concernsabouthumanvitreoussamples
preparation
3.2.1. Hyaluronicacideffect
Hyaluronic acid (HA) is the most important cause of the vis-
cosity of the vitreous. The viscosity may play an important
role in separation therefore, to determine the role of HA in
theseparationofvitreousaminoacids,hyluronidase(HAase)
was used to degrade HA in the vitreous samples. Vitreous
samples were incubated with HAase for 1 to 3 hours with
diﬀerent volume ratios ranging from 1:1 to 1:5 (HAase: vit-
reous;μl), and then evaluated by CE-LIF analysis. We found
that there was no signiﬁcant change in peak heights and al-
though there was a slight increase in retention time (data not
shown). Our results indicate that the presence of hyaluronic
acid does not aﬀect the ability to separate amino acids.
3.2.2. Vitreoussamplestabilitystudyovertime
Another concern was the stability of the vitreous samples es-
pecially since samples in our situation are shipped from sev-
eral locations. It is well known that vitreous sample contains
a variety of proteolytic enzymes that would break down pro-
teins to small peptides and free amino acids. The activity
of those proteolytic enzymes might cause an overestimation
of amino acid levels. In general, the enzyme activity is pH
dependent and most of the proteolytic activity is degraded
when the pH is below 4 so 1M acetic acid solution was intro-
duced to vitreous samples. In addition to clarify the vitreous
sample’s stability over time vitreous samples were evaluatedMiao-Jen Lu et al. 5
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Figure 5: Electropherogram comparison for (a) MH and (b) PDR
in MEKC-PEO method. Patient with MH has simpler peak pattern
than PDR and MH group had better resolution than PDR.
when they arrived, at two weeks and at one month by CE-
LIF analysis. The electropherograms of the vitreous samples
at initial determination and at two weeks begin to show a
degradationthatisenhancedbyonemonth.Figures4(a)and
4(b) are representative electropherograms from diﬀerent pa-
tients. Figure 4(a) shows that the stability of vitreous sam-
ple over one month is decreased while in Figure 4(b) the vit-
reous sample had been analyzed at three days and ten days
following collection and showed minor changes. Therefore,
aminoacidanalysisofvitreoussampleshouldbedonewithin
1 week for quantitative accuracy.
3.3. InvestigationofPDRandERM/MH
Based upon a comparison of the electropherograms of sam-
ples from the PDR and control groups, the peak patterns be-
tween PDR and ERM/MH group appeared markedly diﬀer-
ent (see Figure 5). The peak pattern of PDR group is more
complexthanERM/MHgroup.Thereweremorepeaksinthe
PDRelectropherogramsandtheresolutioninthePDRgroup
was not as good as ERM/MH group. This suggests that the
vitreous samples from patients with PDR contain a greater
amount and an increase in the types of proteins and small
peptides.
Toquantitatethediﬀerencesinthesignalingaminoacids,
peak heights averaging was used to determine the concen-
trations. The summary of the Arg and Glu levels of the
ERM/MHandPDRgroupsareshowninFigure 6.Glutamate
levels for the groups are: PDR = 3.08±0.65μM( n = 18) and
ERM/MH = 0.91 ± 0.08μM( n = 24) (P<. 005). The results
here conﬁrm and add to the few prior studies showing an el-
evation of glutamate with PDR [6, 7]. Arginine levels were
also signiﬁcantly higher: PDR = 35.99 ± 2.93μM( n = 18)
and ERM/MH = 19.98 ±2.89μM( n = 24) (P<. 005).
Therearediﬀerencesinthedegreesofvitrealhemorrhage
among the patients in this study that may cause variances in
the observed amino acid levels. The concentration of blood
isgenerallyhigherthanwhatismeasuredhereinthevitreous
such that leakage from blood could cause an increase in the
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Figure 6: Human vitreous Arg and Glu levels in control and PDR
groups. Each bar represents the mean ± SEM of numbers of sub-
jects. There were signiﬁcant diﬀerences between Arg and Glu levels
of control and PDR groups (∗P<. 05).
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Figure 7: Bargraph of theArgand Glu levels inPDR groupaccord-
ing to extent of vitreal hemorrhage. The gradations of hemorrhage
were classiﬁed as follows: 0: none, +1: mild, +2: moderate, and +3:
severe. Signiﬁcance is determined by one-way ANOVA P<. 05.
levels of glutamate seen in the vitreous [17]. To account for
this, the PDR group was broken into three levels of vitreous
hemorrhage. In Figure 7 there is a bar graph of the means
± S E Mo ft h eA r ga n dG l uc o n c e n t r a t i o n si ne a c hg r o u p .
There is a signiﬁcant decrease in the Glu level with increas-
ing severity of vitreous hemorrhage (P<. 05) while there is
no diﬀerence in the observed Arg concentration. These data
are somewhat surprising but demonstrate the power of our
quantiﬁcationmethod.ThechangesobservedinGlu,butnot
Argsuggestthattherearelikelyneurochemicalchangesatthe
retina prior to observable hemorrhage that may be leading
the damage at the diabetic retina.
In conclusion, we describe the use of micelle coupling
with PEO as a sieving matrix for small molecules analysis
in bodily ﬂuid. This new MEKC-PEO method allowed us to6 Experimental Diabetes Research
do the amino acid analysis of vitreous with faster separation
and better resolution. In addition, we have found that addi-
tion of acetic acid to vitreous samples allows determination
of amino acids for up to two weeks following collection. Fi-
nally, we conﬁrm that PDR causes a statistically signiﬁcant
elevation in glutamate levels and also show that arginine lev-
els are elevated.
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